Cargando…
2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
BACKGROUND: Urinary tract infections (UTIs) caused by extended spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) pose a significant challenge due to limited treatment options. The objective of this study was to compare outcomes in patients treated with standard IV therapy...
Autores principales: | Hefler, Jade L, Perez, Katherine K, Musick, William L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809623/ http://dx.doi.org/10.1093/ofid/ofz360.1939 |
Ejemplares similares
-
Experience with fosfomycin in the treatment of complicated urinary
tract infections caused by extended-spectrum beta-lactamase-producing
Enterobacteriaceae
por: Bielen, Luka, et al.
Publicado: (2019) -
135 Fosfomycin Susceptibilities Among Uropathogenic Extended Spectrum Beta-Lactamase-producing Enterobacteriacea
por: Abbo, Lilian, et al.
Publicado: (2014) -
1472. Non-Carbapenems for Treating Community-Associated Urinary Tract Infection Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Children
por: Joo Jung, Hyun, et al.
Publicado: (2019) -
Antimicrobial Susceptibilities of Urinary Extended-spectrum β-lactamase Escherichia coli to Fosfomycin
por: Saeed, Nermin Kamal, et al.
Publicado: (2021) -
Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens
por: Banerjee, Sayantan, et al.
Publicado: (2017)